Interaction between dietary conjugated linoleic acid and calcium supplementation affecting bone and fat mass
- 218 Downloads
Dietary conjugated linoleic acid (CLA) has shown wide biologically beneficial effects, such as anticancer, antiatherosclerotic, antidiabetic, immunomodulating, and antiobesity effects. However, the effects of CLA on total body ash, reflective of bone mineral content, have not been consistent. We hypothesized that the inconsistency of the CLA effect on ash may be linked to interaction between CLA and dietary calcium levels. Thus, we investigated the effects of CLA on body ash in conjunction with various calcium levels. Male ICR mice were fed three different levels of calcium (0.01, 0.5, and 1%) with or without 0.5% CLA for 4 weeks for Experiment 1 and separate CLA isomers at 0.22% level with 1% calcium in Experiment 2. CLA feeding reduced body fat regardless of dietary calcium level, whereas CLA supplementation increased body ash compared to control only in animals fed the 1% calcium. In Experiment 2 it was confirmed that this observation was associated with the trans-10, cis-12 CLA isomer, but not with the cis-9, trans-11 isomer. CLA administration with 1% dietary calcium significantly improved total ash percent (%) in femurs, confirming that CLA has the potential to be used to improve bone mass.
KeywordsConjugated linoleic acid CLA Bone Calcium Body fat
This work was supported in part by the USDA CSREES MAS00919. We thank Ms. Jayne M. Storkson for assistance with manuscript preparation. We also thank Mr. Siyeon Rhee and Dr. Gang Yong Park (supported by the Charm Sun Jin Food Corporation) for technical assistance and discussion. Mr. Michael Terk was the recipient of the Crabtree scholarship at the College of Natural Resource and Environment, University of Massachusetts, Amherst. Dr. Yeonhwa Park is one of the inventors of the CLA use patent assigned to the Wisconsin Alumni Research Foundation.
- 22.Burr LL, Taylor CG, Weiler HA (2006) Dietary conjugated linoleic acid does not adversely affect bone mass in obese fa/fa or lean Zucker rats. Exp Biol Med (Maywood) 231:1602–1609Google Scholar
- 38.Nuttall ME, Gimble JM (2000) Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone (NY) 27:177–184Google Scholar
- 44.Park Y, Storkson JM, Liu W, Albright KJ, Cook ME, Pariza MW (2004) Structure–activity relationship of conjugated linoleic acid and its cognates in inhibiting heparin-releasable lipoprotein lipase and glycerol release from fully differentiated 3T3-L1 adipocytes. J Nutr Biochem 15:561–568PubMedCrossRefGoogle Scholar
- 45.Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW (2005) Biological activities of conjugated fatty acids: conjugated eicosadienoic (conj. 20:2delta(c11, t13/t12, c14)), eicosatrienoic (conj. 20:3delta(c8, t12, c14)), and heneicosadienoic (conj. 21:2delta(c12, t14/c13, t15)) acids and other metabolites of conjugated linoleic acid. Biochim Biophys Acta 1687:120–129PubMedGoogle Scholar
- 54.Kreider RB, Ferreira MP, Greenwood M, Wilson M, Almada AL (2002) Effects of conjugated linoleic acid supplementation during resistance training on body composition, bone density, strength, and selected hematological markers. J Strength Condit Res 16:325–334Google Scholar
- 67.Naumann E, Carpentier YA, Saebo A, Lassel TS, Chardigny JM, Sebedio JL, Mensink RP, FunCLA Study Group (2006) Cis-9,trans-11 and trans-10,cis-12 conjugated linoleic acid (CLA) do not affect the plasma lipoprotein profile in moderately overweight subjects with LDL phenotype B. Atherosclerosis 188:167–174PubMedCrossRefGoogle Scholar
- 68.Park Y, Pariza MW (2009) Bioactivities and potential mechanisms of action for conjugated fatty acids. Food Sci Biotechnol 18:586–593Google Scholar